Muhammad Irfan Bashir

Mr. Muhammad Irfan Bashir


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2022 in Behavioral Sciences
Verified
Journal Article
Open access
PDF file
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
DNDzul Azri Mohamed Noor
Dzul Azri Mohamed Noor
Depression is the most common behavior disorder that leads to many disabilities. The main aim of this study was to evaluate the effects of a Polygonum minus (P. minus) aqueous extract on chronic ultra-mild stress (CUMS)-induced depressive mice model. Chronic ultra-mild stress can disturb the neurotransmitters levels and plasticity of the hippocampus. Balb/c male mice were used in this study, which consisted of six groups (n = 14). Treatment was given for eight weeks, and chronic ultra-mild stress was applied for six weeks. Commercially available P. minus extract (BioKesum®) was used in this study. The behavior and neurochemical parameters were investigated through behavioral Tests and ELISA assays. P. minus administration significantly (p < 0.05) restored CUMS-induced behavior abnormalities, decreased the immobility time, and increased the sucrose preference and increased the spatial memory. P. minus treatment also showed the decreased level of serum corticosterone and increased the level of hippocampal neurotransmitters (Serotonin and Norepinephrine) significantly (p < 0.05). The brain-derived neurotrophic factor (BDNF) level also increased significantly in both the prefrontal cortex and hippocampus (p < 0.05). P. minus treatment exhibited significant (p < 0.05) reduction of Monoamine Oxidase-A (MAO-A) in the hippocampus. These findings indicate that P. minus aqueous extract exhibits antidepressant effects, including decreased immobility time, increased spatial memory, reduced corticosterone, increased BDNF level, and reduced MAO-A enzyme level with increasing the monoamines (serotonin and norepinephrine) in the hippocampus.

5 June 2019 in Journal of Pharmaceutical Research International
Verified
Journal Article
Open access
PDF file
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
USUzma Saleem
Uzma Saleem
FAFareeha Anwer
Fareeha Anwer
BABashir Ahmad
Bashir Ahmad
Aim: To evaluate the combined and individual effects of thioxanthene containing antipsychotic and anti-platlet drug on Mean Platelet Volume (MPV) and Platelet Distribution Width (PDW) in rats. Methods: This investigational study comprised of 100 albino rats of both sexual orientation, they were of 300 g to 350 g. We got ten groups, in which each group consisted of 10 rats (n=10).Ozagrel was used as anti-platelet and Zuclopenthixol was used as thioxanthene containing antipsychotic. Rats were treated with defined doses of Ozagrel and thioxanthene containing anti-psychotic (Zuclopenthixol) alone and in joined for three weeks (21 days). Blood test at 0, seventh, fourteenth and last day of study were taken. Mean Platelet Volume and Platelet Distribution Width were estimated from blood tests by using standard research center procedure. Results were accumulated and abridged by applying statistics. Correlation was framed between all days incentive to zero day values. Results: Anti-psychotic drug and antiplatelet drug both showed decrease in MPV with both doses highly significantly (p < 0.001) decrease associated with maximum doses alone and with combination group. In case of PDW all individual and minimum combination group showed increase in PDW values but significantly (p < 0.001) increase in maximum combination groups. Conclusion: Combination of both drugs can cause more decrease in MPV as compare to the individual and in case of PDW combination with maximum doses may cause decrease in values by opposing the results individual therapy. It indicated any Drug-Drug interaction between these two drugs regarding Mean platelet volume and Platelet distribution width.

28 July 2022 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
NANur Hidayah Kaz Abdul Aziz
Nur Hidayah Kaz Abdul Aziz
DNDzul Azri Mohamed Noor
Dzul Azri Mohamed Noor
Background: Monoamine oxidase-A (MAO-A) enzyme is responsible for the breakdown of monoamines (serotonin and norepinephrine). MAO-A is also a target to treat the depressive disorders. Kruppel-likefactor11(KLF11) and Sirtuin1(SIRT1) are the main transcriptional activators of MAO-A. Polygonum minus (P. minus) aqueous extract showed some neuroprotective properties in previous studies like improved memory and positive mood. The aim of current study was to evaluate the effects of P. minus aqueous effects on KLF11 and SIRT1 levels in hippocampus of stressed mice. Materials and Methods: Balb/c mice (22g-26g) were used in this study and P. minus aqueous extract was administered for 8 weeks with three different doses (P. minus 50mg, P. minus 100 mg and P. minus 200mg) in different groups. Amitriptyline 20 mg was used as positive control antidepressant. Chronic ultra-mild stress protocol was used for 6 weeks to induce the depression among mice groups except control group. Results: The results showed that all doses of P. minus reduce the KLF11 level significantly but only P. minus 200mg showed reduction in SIRT1 level in hippocampus of mice significantly. Conclusion: It is concluded that P. minus aqueous extract treatment showed a significant reverse in an elevated level of KLF11 and SIRT1 in hippocampus of stressed mice after treatment of 8 weeks

31 August 2025 in Pakistan BioMedical Journal
Verified
Journal Article
Open access
PDF file
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
Insulin resistance is the key parameter in development of type 2 diabetes and also leads to various metabolic disorders globally. Recent evidences demonstrate the vital role of glycemic index (GI) and glycemic load (GL) in glucose metabolism and insulin sensitivity. The glycemic index determines how quickly carbohydrates-rich food elevate the glucose levels in the blood. While Glycemic load represents both quality and quantity of carbohydrates which are consumed. Actually, these factors are directly involved in glucose spike in the blood that is further responsible of insulin secretions. An increased demand of insulin can increase the secretions of insulin from pancreatic beta cells. Increased level of insulin (hyperinsulinemia) can cause insulin resistance. It happens when cells in the body, specifically in muscle, fat, and liver tissues show less response to insulin's signal to take up glucose from the bloodstream. Recent studies has demonstrated through various randomized clinical trials that there is an important link between GI and insulin resistance. They showed that low GI-index foods can reduce the spike of blood glucose level which further can reduce the insulin secretions that can reduce the insulin resistance. A high GI-index diet can cause metabolic dysfunctions in non-diabetic adults [1]. Another research linked higher dietary GI and GL with increased pancreatic steatosis risk, describing the metabolic burden that high GI-index diet affect the pancreatic health [2]. Furthermore, some investigations have suggested that diets with high GI and GL could exacerbate insulin resistance, potentially very serious outcomes in inflammatory conditions such as COVID-19 [3]. All these studies recommend dietary modifications to control or reverse the type 2 diabetes. The use of low GI and low GL based diet can protect individuals from type 2 diabetes. Specifically, we have to modify our daily diet like grain flour, white rice, starchy vegetables, and sugary food. All these foods are high in GI and GL. More concerning for type 2 diabetes patients if they are taking medications but don’t want to modify their diet, they are just supressing their type 2 diabetes with medicines not cutting the roots of this dietary disorder. People got this disorder from their dinning tables but for cure they rely on clinics only, it is better if they first change their food placed dining tables. May be this modification can protect them from continuous visits of clinics and pharmacies. Public health policies and clinical guidelines should incorporate the GI and GL considerations to reduce the growing burden of insulin resistance and its complications effectively. In conclusion, understanding about GI and GL is very important in both diabetes management and prevention. These factors will open new strategies to cope the type 2 diabetes and other metabolic disorders as well. Future research should continue to design the low GI and low GL based personalized nutritional approaches for reducing the insulin resistance.

30 November 2025 in Pakistan BioMedical Journal
Verified
Journal Article
Open access
PDF file
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
Currently, there is a need for novel therapeutic strategies for Alzheimer’s disease (AD) due to the rising global burden. Although some drugs can target amyloid-β and tau pathologies, but still cognitive decline has not been resolved. Advanced research focusing on the Blood-Brain Barrier (BBB) as a therapeutic target for AD, because BBB dysfunction significantly contributes to AD pathogenesis. Emerging evidence shows that BBB dysfunction leads to AD through alterations of endothelial tight junctions, pericyte loss, basement membrane degradation, and impaired clearance mechanisms of amyloid-β waste from the brain and increases the permeability of neurotoxins inside the brain. This dysfunction leads to severe neurodegenerative events [1]. Possibly, the integrity of the BBB can be restored by protecting or repairing the structural and functional components of the BBB for homeostasis purposes, reducing the infiltration of peripheral inflammatory mediators, and supporting the normal clearance of soluble amyloid. Another key issue in AD treatment is the very low penetration of the drug inside the central nervous system (CNS). If the drug delivery system becomes better and a maximum amount of the drug can be penetrated inside the brain, it will also be a big milestone against AD progression. A recent study shows that nanomedicine engineered to engage the BBB transport mechanisms led to robust amyloid clearance and memory recovery in AD model mice [2]. Meanwhile, some studies also focus on finding new biomarkers and therapeutic targets to treat AD. There is a need to search for new targets that are associated with neurodegeneration [3]. There is a need to resist BBB dysfunction; once BBB damage becomes irreversible, then many challenges will become hurdles in AD treatment. Researchers should work to protect the BBB from irreversible damage. In conclusion, we may get proper therapy for Alzheimer’s Disease if we focus on seeking new therapeutic targets, restoring the BBB integrity and developing novel therapeutic strategies that can increase the availability of drugs inside the brain.

12 June 2019 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
MBMuhammad Irfan Bashir
Muhammad Irfan Bashir
Objective: The objective of this study was to investigate the combined as well as individual effects of a typical antipsychotic and thromboxane A2 synthase inhibitor on albumin and total protein level with minimum and maximum dose comparison in rats. Methods: This study consisted of 100 albino rats of 300 to 340 g from both gender, there were 10 groups, each contained 10 rats (n=10). Rats were treated with defined dose of zuclopenthixol (Zuclo) and ozagrel (Ozg) for 21 days (3 weeks). Blood samples were collected at 0, 7th, 14th, and 21st days of study. Albumin and total protein level were examined from blood samples using standard laboratory procedure. Results are extracted by applying statistical analysis on data and comparing percentage variation from 0-day value. Results: A typical antipsychotic-treated group showed gradually significant increase in albumin and total protein level, TXA2 synthase inhibitor-treated group also showed significant gradually increase in albumin and total protein level in combination groups, they showed highly significant increase p<0.001 in both parameter with maximum dose. Conclusion: Combination treatment with zuclopenthixol (Zuclo) and ozagrel (Ozg) can cause large increase on albumin and total protein level with maximum dose as compare to individual drug treatment.